We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva Targets AstraZeneca's Patent on Blockbuster Seroquel
Teva Targets AstraZeneca's Patent on Blockbuster Seroquel
September 30, 2005
Teva Pharmaceutical has filed an abbreviated new drug application (ANDA) to market a generic version of AstraZeneca’s schizophrenia treatment Seroquel, one of two drugs key to AstraZeneca’s future growth after several recent setbacks.